An Open-label, Randomized, Single-dose, 2-sequence, 2-period, Crossover Study to Evaluate the Safety and Pharmacokinetics of AD-227 Compared to Co-administration of AD-227A and AD-227B in Healthy Adult Volunteers Under Fasting Conditions
Latest Information Update: 25 Mar 2025
At a glance
- Drugs AD 227 A (Primary) ; AD 227 B (Primary)
- Indications Essential hypertension
- Focus Pharmacokinetics
- Sponsors Addpharma
- 25 Mar 2025 New trial record